The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
PNPLA3 I148M polymorphism and progressive liver disease
Open accessAbstract
The 148 Isoleucine to Methionine protein variant (I148M) of patatin-like phospholipase domain-containing 3 (PNPLA3), a protein is expressed in the liver and is involved in lipid metabolism, has recently been identified as a major determinant of liver fat content. Several studies confirmed that the I148M variant predisposes towards the full spectrum of liver damage associated with fatty liver: from simple steatosis to steatohepatitis and progressive fibrosis. Furthermore, the I148M variant represents a major determinant of progression of alcohol related steatohepatitis to cirrhosis, and to influence fibrogenesis and related clinical outcomes in chronic hepatitis C virus hepatitis, and possibly chronic hepatitis B virus hepatitis, hereditary hemochromatosis and primary sclerosing cholangitis. All in all, studies suggest that the I148M polymorphism may represent a general modifier of fibrogenesis in liver diseases. Remarkably, the effect of the I148M variant on fibrosis was independent of that on hepatic steatosis and inflammation, suggesting that it may affect both the quantity and quality of hepatic lipids and the biology of non-parenchymal liver cells besides hepatocytes, directly promoting fibrogenesis. Therefore, PNPLA3 is a key player in liver disease progression. Assessment of the I148M polymorphism will possibly inform clinical practice in the future, whereas the determination of the effect of the 148M variant will reveal mechanisms involved in hepatic fibrogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“As for predisposing genetic factors, the I148M PNPLA3 single-nucleotide polymorphism (SNP) has been identified as a major common genetic determinant of MASH severity and outcome(220), while several other gene variants are also likely to modify”
From The liver as a central "hub" of the immune system: pathophysiological implications (2025) · cites this paper as [220]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
I148M PNPLA3 variant and progressive liver disease: A new paradigm in hepatology
Valenti, L. V. C., Alisi, A., & Nobili, V. (2012) · Hepatology · doi:10.1002/hep.25634 · Cited by 33
RetractedTwo new Later Stone Age sites from the Final Pleistocene in the Falémé Valley, eastern Senegal
Ndiaye, M., Lespez, L., Tribolo, C., Rassé, M., Hadjas, I., Davidoux, S., Huysecom, É., & Douze, K. (2024) · Monash University Research Portal (Monash University) · doi:10.3929/ethz-b-000667478 · Cited by 24,214
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.010 · Cited by 2,918
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Williams, C. D., Stengel, J. Z., Asike, M., Torres, D. M., Shaw, J. C., Contreras, M., Landt, C. L., & Harrison, S. A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,182
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Targher, G., Day, C. P., & Bonora, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912063 · Cited by 1,907
Bugianesi, E., Leone, N., Vanni, E., Marchesini, G., Brunello, F., CARUCCI, P., Musso, A., Paolis, P. D., Capussotti, L., Salizzoni, M., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.34168 · Cited by 1,436
Cited by
Sorted by citations
Items 201–250 of 250
Hofseth, L. J., Weston, A., & Harris, C. C. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm023.pub2 · Cited by 4
Deciphering significances of autophagy in the development and metabolism of adipose tissue
Liu, Z., Peng, H., Liu, P., Duan, F., Yang, Y., Li, P., Li, Z., Wu, J., Chang, J., Shang, D., et al. (2025) · Experimental Cell Research · doi:10.1016/j.yexcr.2025.114478 · Cited by 3
Lombardi, R., Forlano, R., Maffi, G., Cespiati, A., Cinque, F., Bignamini, D., Dongiovanni, P., Francione, P., Sigon, G., Huang, J. V., et al. (2025) · Digestive and Liver Disease · doi:10.1016/j.dld.2025.05.011 · Cited by 3
Self-citationCruz, A. A., Hernández, J. C. N., Garza, L. E. C., Miranda‐Duarte, A., Mata-Tijerina, V., Hernández-García, M. E., Peñuelas-Urquides, K., González-Escalante, L. A., de León, M. B., & Silva-Ramírez, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157409 · Cited by 3
Lin, Y., Tsai, Y., Tsai, M.-J., Huang, P., Chen, C., Yao, C., Chuah, S., Kuo, Y., Tai, W., Lian, W., et al. (2024) · Advances in digestive medicine · doi:10.1002/aid2.13367 · Cited by 3
The pharmacological treatment of nonalcoholic fatty liver disease in children
Crudele, A., Panera, N., Braghini, M. R., Balsano, C., & Alisi, A. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1829468 · Cited by 3
Zhang, H., Li, X., Chen, L., Jiang, S., Xin, Y., & Xuan, S. (2015) · Hepatitis Monthly · doi:10.5812/hepatmon.31987 · Cited by 3
Predictive risk markers in alcoholism
Niemelä, O. J. (2023) · Advances in clinical chemistry · doi:10.1016/bs.acc.2023.05.002 · Cited by 3
The impact of genetic polymorphisms on liver diseases: entering the era of personalized medicine
Boccuto, L., & Abenavoli, L. (2017) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000917 · Cited by 3
Celsa, C., Pennisi, G., Tulone, A., Ciancimino, G., Vaccaro, M., Pecorella, F., Maria, G. D., Enea, M., Targher, G., Valenti, L. V. C., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101918 · Cited by 4
Färkkilä, M. A., Kautiainen, H., Tenca, A., Jokelainen, K., & Arola, J. T. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277084 · Cited by 2
Risk of Liver Cancer in MASLD: Role of Genetic Risk Scores
Maccali, C., Pereira, I. V. A., Stefano, J. T., & de Oliveira, C. P. M. S. (2023) · Current Hepatology Reports · doi:10.1007/s11901-023-00623-6 · Cited by 2
The Natural History of NAFLD: Environmental vs. Genetic Risk Factors
Valenti, L., & Pelusi, S. (2020) · Springer eBooks · doi:10.1007/978-3-319-95828-6_7 · Cited by 2
Lombardi, R., Colavolpe, L., Alletto, F., Cespiati, A., Fatta, E., Bertelli, C., Cinque, F., Pisano, G., Pulixi, E. A., Francione, P., et al. (2023) · Digestive and Liver Disease · doi:10.1016/j.dld.2023.07.009 · Cited by 2
Self-citationAzariadis, K., Gatselis, N., Lyberopoulou, A., Arvaniti, P., Zachou, K., Gabeta, S., & Dalekos, G. Ν. (2024) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2024.100243 · Cited by 2
Down-regulation of hepatic MBOAT7 by hyperinsulinemia favors steatosis development
Meroni, M., Dongiovanni, P., Rametta, R., Bassani, G. A., Badiali, S., Fargion, S. R., Romeo, S., Gatti, S., & Valenti, L. V. C. (2017) · Journal of Hepatology · doi:10.1016/s0168-8278(17)31627-6 · Cited by 2
Self-citationNon-Alcoholic Fatty Liver Disease and Steatohepatitis
Govaere, O., & Anstee, Q. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00265-0 · Cited by 2
Du, S.-X., Yin, J., Hu, K., & Xin, Y. (2025) · Hepatitis Monthly · doi:10.5812/hepatmon-160524 · Cited by 1
Zheng, Z., Huang, Y., Zhang, J., Xie, J., Pan, A., Liao, Y., & Zhang, Y. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.102136 · Cited by 1
Podeanu, M.-A., Sandu, R. E., Vintilescu, Ş. B., Ionele, C. M., Rogoveanu, I., Streață, I., Niculescu, C., Florescu, D. N., Cazacu, S. M., Andrei, Ș. C., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073044 · Cited by 1
Kim, J., Lee, H. G., & Shin, M. (2026) · Nucleic Acid Therapeutics · doi:10.1177/21593337251415115 · Cited by 1
Tauriainen, M.-M., Lankinen, M. A., Hakumäki, J. M., Lahtinen, O., Husso, M., Ågren, J. J., Laakso, M., & Schwab, U. (2026) · European Journal of Nutrition · doi:10.1007/s00394-026-04031-6 · Cited by 2
Autophagy in MASLD : A Metabolic and Precision Medicine Perspective
Cazzaniga, A., Frigo, S., Cherubini, A., Rrapaj, E., & Valenti, L. V. C. (2026) · Liver International · doi:10.1111/liv.70816 · Cited by 1
Mackawy, A. M. H., Badawi, M. E., & Megahed, O. (2015) · Egyptian Journal of Medical Human Genetics · doi:10.1016/j.ejmhg.2015.06.001 · Cited by 1
Alcoholic Liver Disease: From Bench to Bedside
Abenavoli, L. (2019) · Reviews on Recent Clinical Trials · doi:10.2174/157488711403190718125454 · Cited by 1
Genetic predictors and pathophysiological features of non-alcoholic fat liver disease
Smirnova, O. V., Moskalenko, O. L., Каспаров, Э. В., & Каспарова, И. Э. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-15-78-87 · Cited by 1
Down-regulation of hepatic MBOAT7 by hyperinsulinemia favors steatosis development
Meroni, M., Dongiovanni, P., Longo, M., Rametta, R., Badiali, S., Fargion, S., Romeo, S., Gatti, S., & Valenti, L. V. C. (2018) · Journal of Hepatology · doi:10.1016/s0168-8278(18)30280-0 · Cited by 1
Self-citationАлексеевич, К. Х., Pavlova, N. I., Diakonova, A., Sydykova, L. A., Markova, S. V., & Владимирович, Д. В. (2020) · International Journal of Biomedicine · doi:10.21103/article10(4)_oa21 · Cited by 1
Ashraf, M. U. (2022) · Gastroenterology & Hepatology International Journal · doi:10.23880/ghij-16000134 · Cited by 1
Danielsson, J. (2014) · Tampere University Institutional Repository (Tampere University) · Cited by 1
Paolini, E., Longo, M., Meroni, M., Podini, P., Maggioni, M., Quattrini, A., Fracanzani, A. L., & Dongiovanni, P. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.06.592717 · Cited by 1
Self-citationJohnson, K. B. (2014) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Reply to “Statin treatment for non-alcoholic steatohepatitis”
Dongiovanni, P., Pihlajamäki, J., Romeo, S., & Valenti, L. V. C. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.09.023
Self-citationPNPLA3 Variant p.I148M and Bariatric Surgery
Liebe, R., Lammert, F., & Krawczyk, M. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804011-9.00051-0
Алексеевич, К. Х., Pavlova, N. I., Dyakonova, A. T., Соловьева, Н. А., Soloveva, Y. A., Sydykova, L. A., Филиппова, Н. П., & Александрова, Т. Н. (2019) · Современные проблемы науки и образования · doi:10.17513/spno.28768
Mechanisms of Fibrogenesis in NASH
Pastore, M., Gentilini, A., & Marra, F. (2020) · Springer eBooks · doi:10.1007/978-3-319-95828-6_6
Diakonova, A., Куртанов, Х. А., Pavlova, N. I., & Aleksandrova, T. (2021) · International Journal of Biomedicine · doi:10.21103/article11(1)_oa16
Personalised medicine for Non-Alcoholic Fatty Liver Disease
Taylor, A. (2021) · Discovery Research Portal (University of Dundee)
Altamirano, J., Orman, E. S., & Bataller, R. A. (2015) · Wiley eBooks · doi:10.1002/9781118512074.ch103
Corella, D. (2018) · MDPI eBooks · doi:10.3390/books978-3-03842-996-8 · Cited by 1
Ata, D. S., Awad, M. A. E., Eid, M. A. E.-W., ElShafey, K. I., & Taha, O. (2021) · Alexandria Journal of Pediatrics · doi:10.4103/1687-9945.337830
Hofseth, L. J., Weston, A., & Harris, C. C. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm023
Amirkulova, A., Derbissalina, G., Benberin, V. V., Shanazarov, N. A., Abildinova, G. Z., Kozhakhmet, D., & Katchman, H. (2023) · Electronic Journal of General Medicine · doi:10.29333/ejgm/13718
Non-Alcoholic Fatty Liver Disease : Insights into Alcohol Consumption, Genetics, and Proteomics
Blomdahl, J. (2023) · Linköping University medical dissertations · doi:10.3384/9789180752923
Khurram, N. A. (2025) · Pracatical anatomic pathology · doi:10.1007/978-3-031-97506-6_15
Arriaga-González, F. G., Castañeda-Córdova, F. D. J., Díaz‐Muñoz, M., Hoare, M., Adams, D., Robles‐Espinoza, C. D., & Molina‐Aguilar, C. (2026) · BMC Medical Genomics · doi:10.1186/s12920-026-02332-7 · Cited by 1
Diversité des macrophages dans un modèle murin de stéatohépatite non alcoolique
Tran, S. (2019) · theses.fr (ABES) · doi:10.70675/22efc884z2788z43fazabc1zaeb115ea6833
Arthur, G., Adenawoola, M. I., Wahba, S., Montgomery, B., Wingfield, C. B., Kipp, Z. A., Hinds, T. D., & Stec, D. E. (2026) · FASEB BioAdvances · doi:10.1096/fba.2026-00222
Abnormal lipid metabolism in metabolic dysfunction-associated steatohepatitis (MASH)
Lee, W., Choi, Y., Park, H., Chae, S., & Lee, B. (2026) · Toxicological Research · doi:10.1007/s43188-026-00387-3
Metadata
- Authors
- Dongiovanni, P.
- Affiliations
- University of Milan (IT)
- Corresponding author
- Dongiovanni, Paola
- ORCID
- Dongiovanni, Paola
- Venue
- World Journal of Gastroenterology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2013
- Volume
- 19
- Issue
- 41
- Pages
- 6969
- ISSN
- 1007-9327 (ISSN-L)
- PMC
- PMC3819533
- OpenAlex
- W2031119940
- Cited by
- 252
- References
- 103
- Citations by year
- 2026: 11 · 2025: 18 · 2024: 10 · 2023: 26 · 2022: 19 · 2021: 24 · 2020: 25 · 2019: 12 · 2018: 17 · 2017: 23 · 2016: 21 · 2015: 31 · 2014: 15
- FWCI
- 2.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- World Journal of Gastroenterology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- PNPLA3, I148M polymorphism, hepatic steatosis, steatohepatitis, liver fibrosis, fibrogenesis, liver cirrhosis, chronic hepatitis C, chronic hepatitis B, hereditary hemochromatosis, primary sclerosing cholangitis, genetic susceptibility, non-parenchymal liver cells, lipid metabolism
- MeSH terms
- Acyltransferases, Fatty Liver, Fatty Liver, Alcoholic, Hemochromatosis, Carcinoma, Hepatocellular, Humans, Lipase, Liver Cirrhosis, Liver Cirrhosis, Alcoholic, Liver Neoplasms, Membrane Proteins, Phenotype, Polymorphism, Genetic, Risk Factors, Cholangitis, Sclerosing, Disease Progression, Hepatitis B, Chronic, Hepatitis C, Chronic, Genetic Predisposition to Disease, Phospholipases A2, Calcium-Independent, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
